IP Library Granted Patent US 9,399,045
Granted Patent B2
US 9,399,045 · App. 14/927,819 · Granted Jul 26, 2016

Inhibition of choroidal neovascularization

Inventor: Rajendra S. Apte (Clayton, MO)
Assignee: Washington University
A61K35/15A61K9/0019A61K9/0048A61K9/0053A61K31/18A61K31/195A61K31/265A61K31/421A61K31/47A61K31/4706A61K31/575A61K31/58A61K38/1709C12N5/0645C12N15/113C12N2501/999C12N2502/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,399,045
App. No.
14/927,819
Granted
Jul 26, 2016
Kind
B2
Abstract

Methods of treatment of diseases that include or are characterized by inappropriate or pathological neovascularization are disclosed. These diseases include diseases of the eye, such as diabetic retinopathy, retinopathy of prematurity, and choroidal neovascularization which can occur in age-related macular degeneration (AMD). Disclosed methods include applying to macrophages in cell culture an agent that causes upregulation of ABCA1 transporter protein, and administering the macrophages to a subject. The agents include, without limitation, LXR agonists. Administration routes can include, without limitation, intraocular, periocular, and systemic administration.

Claims (12)

1. A method of treating an ocular disease characterized by choroidal neovascularization (CNV) in a subject in need thereof, comprising:

providing a cell culture comprising macrophages; adding an activator of an ATP-binding cassette (ABC) transporter to the culture in an amount sufficient to stimulate ABC transporter expression and/or activity in the macrophages; and

administering the macrophages to the subject.

2. A method in accordance with claim 1 , wherein the activator is N-(2,2,2-trifluoroethyl)-N-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide.

3. A method in accordance with claim 1 , wherein the activator is methyl-3β-hydroxy-5α,6α-epoxycholanate.

4. A method in accordance with claim 1 , wherein the activator is 2-[3-[3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]propoxy]phenyl]acetic acid.

5. A method in accordance with claim 1 , wherein the providing a cell culture comprising macrophages comprises providing a cell culture comprising peripheral blood mononuclear cells (PBMCs).

6. A method in accordance with claim 3 , wherein the cell culture comprising peripheral blood mononuclear cells (PBMCs) comprises PBMCs autologous to the subject.

7. A method in accordance with claim 3 , wherein the providing a cell culture comprising macrophages comprises growing macrophages comprised by the culture.

8. A method in accordance with claim 1 , wherein the administering the macrophages to the subject can comprise administering the macrophages to the subject intravenously.

9. A method in accordance with claim 1 , wherein the administering the macrophages to the subject can comprise administering the macrophages to the subject periocularly.

10. A method in accordance with claim 1 , wherein the administering the macrophages to the subject comprises administering the macrophages to the subject intraocularly.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 8, 2016
From: WASHINGTON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039289/0489 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2016
From: APTE, RAJENDRA
To: WASHINGTON UNIVERSITY
Reel/Frame 037976/0111 →
Continuity (5)
Division 14811011 · Jul 28, 2015
Division 13918453 · Jun 14, 2013
Division 13480024 · May 24, 2012
Provisional Application 61489656 · May 24, 2011
Related Publication 20160045549A1 · Feb 18, 2016